Suppr超能文献

胃腺瘤患者背景黏膜的萎缩和化生进展

Atrophic and Metaplastic Progression in the Background Mucosa of Patients with Gastric Adenoma.

作者信息

Na Hee Kyong, Cho Charles J, Bae Suh Eun, Lee Jeong Hoon, Park Young Soo, Ahn Ji Yong, Kim Do Hoon, Choi Kee Don, Song Ho June, Lee Gin Hyug, Jang Se Jin, Jung Hwoon-Yong

机构信息

Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.

Department of Biomedical Science, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.

出版信息

PLoS One. 2017 Jan 10;12(1):e0169456. doi: 10.1371/journal.pone.0169456. eCollection 2017.

Abstract

BACKGROUND

In patients with adenoma, assessing premalignant changes in the surrounding mucosa is important for surveillance. This study evaluated atrophic and metaplastic progression in the background mucosa of adenoma or early gastric cancer (EGC) cases.

METHODS

Among 146 consecutive patients who underwent endoscopic resection for intestinal-type gastric neoplasia, the adenoma group included 56 patients with low-grade dysplasia and the ECG group included 90 patients with high-grade dysplasia or invasive carcinoma. For histology, 3 paired biopsies were obtained from the antrum, corpus lesser curvature (CLC), and corpus greater curvature (CGC). Serological atrophy was determined based on pepsinogen A (PGA), progastricsin (PGC), gastrin-17, and total ghrelin levels. Topographic progression of atrophy and/or metaplasia was staged using the operative link on gastritis assessment (OLGA) and operative link on gastric intestinal metaplasia assessment (OLGIM) systems.

RESULTS

Rates of moderate-to-marked histological atrophy/metaplasia in patients with adenoma were 52.7%/78.2% at the antrum (vs. 58.8%/76.4% in EGC group), 63.5%/75.0% at the CLC (vs. 60.2%/69.7% in EGC group), and 10.9%/17.9% at the CGC (vs. 5.6%/7.8% in EGC group). Serological atrophy indicated by PGA and PGC occurred in 23.2% and 15.6% of cases in the adenoma and ECG groups, respectively (p = 0.25). Mean serum gastrin-17 concentrations of the adenoma group and EGC group were 10.4 and 9.0 pmol/L, respectively (p = 0.54). Mean serum total ghrelin levels were 216.6 and 209.5 pg/mL, respectively (p = 0.71). Additionally, between group rates of stage III-IV OLGA and OLGIM were similar (25.9% vs. 25.0%, p = 0.90; 41.8% vs. 44.9%, p = 0.71, respectively).

CONCLUSIONS

Atrophic and metaplastic progression is extensive and severe in gastric adenoma patients. A surveillance strategy for metachronous tumors should be applied similarly for patients with adenoma or EGC.

摘要

背景

对于腺瘤患者,评估周围黏膜的癌前病变对于监测很重要。本研究评估了腺瘤或早期胃癌(EGC)病例背景黏膜中的萎缩和化生进展情况。

方法

在146例接受内镜切除的肠型胃肿瘤连续患者中,腺瘤组包括56例低级别异型增生患者,EGC组包括90例高级别异型增生或浸润性癌患者。对于组织学检查,从胃窦、胃体小弯(CLC)和胃体大弯(CGC)获取3对活检组织。根据胃蛋白酶原A(PGA)、胃蛋白酶原C(PGC)、胃泌素-17和总胃饥饿素水平确定血清学萎缩情况。使用胃炎评估手术链接(OLGA)和胃肠化生评估手术链接(OLGIM)系统对萎缩和/或化生的地形进展进行分期。

结果

腺瘤患者胃窦中度至重度组织学萎缩/化生率分别为52.7%/78.2%(EGC组为58.8%/76.4%),CLC为63.5%/75.0%(EGC组为60.2%/69.7%),CGC为10.9%/17.9%(EGC组为5.6%/7.8%)。腺瘤组和EGC组中分别有23.2%和15.6%的病例出现由PGA和PGC提示的血清学萎缩(p = 0.25)。腺瘤组和EGC组的平均血清胃泌素-17浓度分别为10.4和9.0 pmol/L(p = 0.54)。平均血清总胃饥饿素水平分别为216.6和209.5 pg/mL(p = 0.71)。此外,两组之间III-IV期OLGA和OLGIM的发生率相似(分别为25.9%对25.0%,p = 0.90;41.8%对44.9%,p = 0.71)。

结论

胃腺瘤患者的萎缩和化生进展广泛且严重。对于腺瘤或EGC患者,应同样应用异时性肿瘤的监测策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b80/5225017/60f7f5f0c8c9/pone.0169456.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验